QYResearch: The HPV testing revenue is expected to reach $ 858.39 million in 2022
The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The HPV testing is further classified into three sub-segments, namely, follow-up testing, co-testing, HPV primary testing.
The HPV testing revenue was $ 529.75 million in 2016 and is expected to reach $ 858.39 million in 2022, growing at a CAGR of 8.34% from 2017 to 2022.0
According to QYResearch, Global HPV testing market can be divided into two big markets: Europe and USA. USA is the largest HPV testing region, in 2016, USA HPV testing revenue was about $ 248.12 million in 2016, in 2017, USA HPV testing revenue will be about $ 270.49 million.
HPV Testing can be divided into three parts: HPV primary testing, Follow-up HPV Testing and Co-testing. Co-testing is the biggest type, in 2016 Co-testing revenue was about $ 293.53 million and in 2017 Co-testing revenue will be about $ 319.42 million
HPV Testing is mainly used in Cervical Cancer Screening. Cervical Cancer Screening is the biggest application, in 2016 Cervical Cancer Screening revenue was about $ 465.23 million and in 2017 Cervical Cancer Screening revenue will be about $ 508.12 million
The main suppliers of HPV testing in the market include Qiagen, Roche Diagnostics, Hologic, Abbott Laboratories, BD and Seegene, Inc., Qiagen is the biggest supplier, in 2016 Qiagen revenue was about $ 194.13 million and in 2017 Qiagen revenue will be about $ 204.06 million.
This article was first released by QYResearch, if reproduced, please indicate the source.
Marketing: sales@qyresearch.com
Media Contact: press@qyresearch.com
评论
发表评论